IDEAYA Biosciences Inc. Common Stock (IDYA)
Stock · NASDAQ · Health Care
$32.82as of 10/16/2026
Price chart
Active signals
IDYA Signal Track Record
How signals performed across all stocks →What IDYA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +3.8% | 57% | September 17, 2026 |
| Bollinger Band Breakout | 25 | +1.8% | 60% | August 18, 2026 |
| Bollinger Band BreakdownActive now | 23 | -1.8% | 39% | April 27, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -3.9% | 43% | June 17, 2026 |
| Any 20-session window (baseline) | +1.2% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IDYA
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with c…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 145
- Website
- www.ideayabio.com/
Fundamentals
- 1-day range
- $33.62$34.67
- Market cap
- $3.50B
- P/E (trailing)
- —
- P/E (forward)
- -8.22
- EPS (trailing)
- $-1.94
- Dividend yield
- —
- Beta
- 0.05
- Avg. volume
- 780.0K
How IDEAYA Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
IDEAYA Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Ratingbenzinga · 10/16/2026
- IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions GrowYahoo · 10/8/2026
- IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentYahoo · 9/28/2026
- Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key CatalystsYahoo · 9/28/2026
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/25/2026
- Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?Yahoo · 9/25/2026
- IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Hata Yujiro S · October 6, 2026 · Option Exercise26.3K @ $4.31
- Hata Yujiro S · October 6, 2026 · Sale800 @ $38.26
- Hata Yujiro S · October 6, 2026 · Sale25.5K @ $37.39
- Ruiz Briseno Andres · July 7, 2026 · Option Exercise9.6K @ $12.86
- Ruiz Briseno Andres · July 7, 2026 · Sale9.6K @ $40.01
- Stein Jeffrey · June 16, 2026 · Grant20.0K
- ROSEN TERRY J · June 16, 2026 · Grant20.0K
- Wendy L. Yarno · June 16, 2026 · Grant20.0K
- MACKEY CATHERINE J · June 16, 2026 · Grant20.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 95.30M
- Total value held
- $3.13B
- Institutional holders
- 249
- Unknown13.17M
- Unknown8.44M
- Unknown7.27M
- Unknown5.16M
- Unknown3.95M
- Unknown3.78M
- Unknown3.73M
- Unknown3.45M
- Unknown2.99M
- Unknown2.82M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
IDEAYA Biosciences Rethinks R&D Leadership Amid Valuation Questions
IDEAYA Biosciences is reevaluating its research and development leadership structure as questions about the company's valuation grow. This internal restructuring occurs while the stock trades near its support level of $35.91, well below the average analyst target of $52.75. The move signals a strategic shift in how the company approaches its scientific pipeline and cost management.
IDEAYA Biosciences Rethinks R&D Leadership Amid Valuation Questions. IDEAYA Biosciences is reevaluating its research and development leadership structure as questions about the company's valuation grow. This internal restructuring occurs while the stock trades near its support level of $35.91, well below the average analyst target of $52.75. The move signals a strategic shift in how the company approaches its scientific pipeline and cost management.